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Background: Vascular calcification (VC) contributes to high mortality rates in chronic kidney disease (CKD). High
serum phosphate and FGF23 levels and impaired phosphaturic response to FGF23 may affect VC. Therefore, their
relative contribution to abdominal aortic calcification (AAC) was examined in patients CKD stages 3–4.
Methods: Potential risk factors for AAC, measured by the Kauppila Index (KI), were studied in 178 patients.
Results: In multivariate linear analysis, AAC associated positively with age, male gender, CKD-stage, presence of
carotid plaques (CP) and also with FGF23, but negatively with fractional excretion of phosphate (FEP). Intriguingly,
FEP increased with similar slopes with elevations in PTH, with reductions in GFR, and also with elevations in FGF23
but the latter only in patients with none (KI = 0) or mild (KI = 1-5) AAC. Lack of a FEP-FGF23 correlation in patients
with severe AAC (KI > 5) suggested a role for an impaired phosphaturic response to FGF23 but not to PTH in AAC.
Logistic and zero-inflated analysis confirmed the independent association of age, CKD stage, male gender and CP
with AAC, and also identified a threshold FEP/FGF23 ratio of 1/3.9, below which the chances for a patient of
presenting severe AAC increased by 3-fold. Accordingly, KI remained unchanged as FEP/FGF23 ratios decreased
from 1/1 to 1/3.9 but markedly increased in parallel with further reductions in FEP/FGF23 < 1/3.9.
Conclusions: In CKD 3–4, an impaired phosphaturic response to FGF23 with FEP/FGF23 < 1/3.9 associates with
severe AAC independently of age, gender or CP.
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Cardiovascular disease is the main cause of mortality in
chronic kidney disease (CKD) patients [1-4] and vascular
calcification (VC) is a critical contributor to the progres-
sion of vascular lesions [5-7]. For decades, therapy has
been directed to correct abnormalities in phosphate,
calcium, and vitamin D metabolism, all of which cause
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reproduction in any medium, provided the orto VC [8,9]. Currently, the role of the FGF23 in the devel-
opment of VC in the course of CKD is the focus of intense
research, as serum FGF23 increases earlier than either
phosphate or PTH and appears to mark a prolonged posi-
tive phosphate balance. Furthermore, in advanced CKD
stages, as in the dialysis population, extremely high FGF23
levels associate with VC regardless of serum phosphate
[10-12]. However, at earlier stages, conflicting reports exist
as to whether high FGF23 but not serum phosphate [13],
or high phosphate but not FGF23, independently associate
with VC [14]. In support for the latter, neutralization of
FGF23 in a rat model of CKD improves associated hyper-
parathyroidism but increases VC and mortality [15]. How-
ever, in animals with normal renal function, increases inLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phosphaturic and PTH suppressive actions, and also
through a potent inhibition of renal calcitriol production,
which in turn limits intestinal calcium and phosphate
absorption [16,17]. Furthermore, ex-vivo studies in human
arteries and Vascular Smooth Muscle Cells (VSMC) have
demonstrated anti-calcifying rather than pro-calcific ac-
tions of FGF23, provided there is sufficient arterial klotho
for FGF23 actions [18]. Undoubtedly, the contradictory
evidence on the role of high FGF23 on VC in CKD may
result from the inability to discriminate between adaptive
increases in serum FGF23 that translate into an adequate
renal phosphaturic response from further elevations in
FGF23 resulting from the failure of the damaged kidney to
handle the phosphate load. Indeed, Dominguez et al. [19]
have recently shown that in patients with cardiovascular
disease but without CKD, the lower is the phosphaturic
response of the kidney the higher is the association
between serum FGF23 levels and adverse cardiovascular
events. The high impact of VC on adverse cardiovascular
events and mortality risk [20] led us to assess the influ-
ence of an abnormal renal handling of the phosphate/
FGF23 axis on abdominal aortic calcification (AAC) in
CKD patients stages 3 and 4.
High serum FGF23 also induces cardiovascular disease
through mechanisms unrelated to abnormal phosphate
homeostasis [21]. Because high FGF23 correlates directly
with total body atherosclerosis [22], it is possible that high
FGF23 enhancement of atheromatous disease progression
may also contribute to VC. Indeed, in hemodialysis
patients, atheromatous disease is also associated with
arterial intima calcification [23]. Therefore, this work was
designed to evaluate the relative impact of high serum
FGF23 or of an impaired phosphaturic response to FGF23
on the severity of AAC in CKD patients stages 3 and 4.
Methods
Study design
Cross-sectional study that enrolled 205 patients CKD
stages 3 and 4, according to K/DOQI guidelines [24],
from the Division of Nephrology and the UDETMA Unit
at the Hospital Universitario Arnau de Vilanova (HUAV)
in Lleida, Spain. Final sample size was 178, as 27
patients were excluded due to history of primary hy-
perparathyroidism, neoplasia, parathyroidectomy, renal
transplantation, and osteoporosis treated with biphos-
phonates or calcitonin, or treated with steroids (n = 8);
lack of carotid ultrasound evaluating atheromatous lesions
(n = 18), and the one black patient among Caucasians.
Protocols were approved by the committee for human
studies at the HUAV. Informed consent was obtained
from all participants.
Data collected include: age, gender, CKD etiology, pres-
ence of diabetes, hypertension, pulse pressure, smokingstatus and prior history of cardiovascular disease. Esti-
mated glomerular filtration rates (eGFR) were calculated
using the Modification of Diet in Renal Disease (MDRD)
equation [25]. At the time of initiation of recruitment
(January 2008), neither calcium-free phosphate binder nor
paricalcitol were available. Therefore, treatment with
calcium-containing phosphate binders (for serum phos-
phate > 4.5 mg/dl) and/or calcitriol (for serum PTH > 20
pmol/l in CKD stage 3, or >25 pmol/l in stage 4), was
either avoided or minimized in patients with prior history
of vascular or soft tissue calcification.Laboratory data
Fasting venous blood samples and a 24 hour urine
collection were obtained between 8–9 AM, to minimize
daily circadian variations in serum phosphate levels.
Routine tests included lipid profile, serum levels of
glucose, albumin, C reactive protein (CRP), creatinine,
phosphate, calcium, CaxP product, bone-specific alkaline
phosphatase.
Selected parameters of mineral metabolism included:
Serum levels of intact PTH (iPTH; by chemiluminescence
immunoassay (Cobast®, Roche Diagnostics GmbH), 25-
hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin
(calcitriol) by radioimmunoassay (Biosource®) and radiore-
ceptor assay Gamma-B dihydroxyvitamin D, IDS Hybritec®,
respectively. Vitamin D supplementation (400 IU/day) in
vitamin D deficient patients eliminated seasonal differences
in serum 25(OH)D in patients recruited during the winter
(68.8%). Urinary calcium, sodium, and phosphate excretion
in 24 h and their respective fractional excretions (FE)
were measured. FEP = [Urinary P (mg/dl) × Serum Crea-
tinine (mg/dl)] / [Serum P (mg/dl) × Urinary creatinine
(mg/dl)] × 100. Protein intake was estimated using a
standard formula, as previously described [26].
Serum FGF23 and soluble α-Klotho were measured
with Elisa kits for human C-Term FGF23 (Immutopics,
Inc., San Clemente, CA) and for soluble α-Klotho
(Immuno-Biological Laboratories Co., Ltd., Japan), fol-
lowing manufacturer’s protocols with intra- and inter-
assay coefficient of variation of 5%.Measurements of abdominal aortic calcification and
carotid atheromatous disease
AAC measured by the Kauppila index (KI) [27] was
obtained from lateral lumbar X rays, and evaluated
independently by two highly experienced examiners. The
inter-observer coefficient of variation was below 2%.
Carotid ultrasound (MicroMaxx, SonoSite with the
linear transducer HFL38/13-6 MHz) measured the pres-
ence of carotid plaques (CP) and carotid intima-media
thickness (IMT; semi-automated, FDA-approved soft-
ware, Sono Calc IMT®), as previously described [28].
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Data are presented as mean ± SD for quantitative vari-
ables, and as percentage of patients for descriptive,
qualitative variables. A logarithmic transformation of
serum FGF23 allowed achieving a distribution close to
normal. KI tertiles defined patients as: Non-calcified
(KI = 0), moderately calcified: KI values ≥1 up to 5; and
severely calcified: KI higher than 5. The statistical
significance of the differences among the 3 KI-based
subgroups was measured with Kruskal-Wallis for quanti-
tative variables and chi-square tests for qualitative vari-
ables (or Fisher test for expected frequencies below 5).
Differences in KI, FEP and FGF23 among CKD 3 and 4
were assessed using the Kruskal-Wallis test. The Pearson
correlation coefficient measured the linear correlation
between KI values as the dependent variable with each
of every other quantitative variable in bivariate analysis.
A scatterplot, with linear and nonparametric regres-
sion lines assessed the relationship between FEP/FGF23
in logarithmic scale (base 2) with the Kauppila index.
The non parametric regression to delineate mean fitting
was implemented as a local polynomial surface regres-
sion with a smoothing degree of 0.96. For dispersion
from the mean fit, we used an estimate of the square
root of the variance function, with separate smoothing
of the squares of the positive and negative residuals from
the mean fit. This analysis identified the ratio FEP/
FGF23 = 1/3.9 as a critical cutoff point further used in
multivariate analysis. Multivariate linear regression and
logistic regression analyses identified the variables that
contributed significantly to either explain the variability
in KI as a continuous variable, or to discriminate pa-
tients without AAC (KI = 0) or with severe AAC (KI > 5),
respectively. The significance of interaction effects of KI
tertiles on the relationship of FGF23, PTH or eGFR with
FEP was assessed using Likelihood Ratio (LR) tests. The
area under the ROC curve (AUC) assessed the dis-
crimination capability of the logistic model and the
Hosmer-Lemeshow goodness-of-fit tests measured model
calibration. A zero-inflated regression model was used to
simultaneously fit the high frequency of KI = 0 in our
patient population with actual KI scores. Due to over-
dispersion, the Negative Binomial distribution was chosen
over the Poisson distribution to fit KI scores. The explana-
tory variables chosen minimized residual deviance when
comparing hierarchical models according to LR tests. Data
were analyzed using the software: “Statistics for the Social
Sciences” SPSS 11.0, and/or the free software R. For all
tests, a p < 0.05 was considered statistically significant.
Results
Table 1 shows socio-demographical and clinical data in
all patients and in the three subgroups defined by tertiles
of KI. KI subgroups differed in gender, etiology of CKD,smoking status, previous history of cardiovascular
disease (CHF specifically), presence of carotid plaques,
severity of the atheromatous disease, and in the number
of patients receiving treatment with anti-thrombotic and
diuretic drugs at the time AAC was measured. KI sub-
groups also differed in age, pulse pressure, IMT, serum
FGF23 levels, and CaxP product, but had similar serum
creatinine, phosphate, calcium, PTH, estimated GFR,
and daily protein/phosphate intake.
In bivariate analysis, KI associated positively with age (r:
0.419; p < 0.001), pulse pressure (r: 0.209; p = 0.005); IMT
(r: 0.320; p < 0.0001) and log FGF23 (r: 0.242; p = 0.001).
Also, KI was higher at later stages of CKD (3 vs. 4: mean
(SD) of 2.8 (3.29) vs. 4.5 (4.63); Mann–Whitney p = 0.023),
in patients with carotid plaques (4.9 (4.47) vs. 1.3 (2.25);
p < 0.001; smokers (4.8 (4.05) vs. 3.4 (4.37); p =0.004),
history of cardiovascular disease (5.3 (4.53) vs. 3.0 (3.90);
p < 0.001) or receiving diuretics (4.5 (4.33) vs. 2.8 (4.03);
p = 0.005). Interestingly, serum PTH, 25(OH)D, or calci-
triol levels did not associate with KI.
Multivariate regression analyses, using KI as a quantita-
tive variable (Table 2), identified which of the variables
listed in Table 1 were independently associated to AAC in
all patients (Model 1), or in patients with an estimated
GFR below 30 ml/min (Model 2). The latter analysis was
conducted to disregard effects on VC that could result
from marked differences in renal function. Table 2 shows
that age, male gender, CKD stage, presence of carotid
plaques and the log of serum FGF23 associated positively
with KI values, but FEP associated negatively. LR tests
confirmed that neither markers of abnormal mineral
metabolism (high serum P or PTH, or low vitamin D
metabolites) nor any of the other variables tested or con-
ditions predisposing to VC in individuals with normal
renal function (smoking, diabetes, congestive heart failure)
were independently associated with KI scores.
Because serum FGF23 and FEP increase in parallel
with the progressive reductions in renal function in the
course of CKD, the observed inverse association between
FEP and KI suggested a role for resistance to FGF23
phosphaturic actions in the severity of AAC. Indeed,
linear regression analyses between serum FGF23 and
FEP as the dependent variable (Figure 1A), discriminat-
ing non-calcified patients (KI = 0) from those moderately
(KI = 0-5) or severely (KI > 5) calcified, showed almost
identical slopes for non-calcified (r = 0.28; p < 0.033) or
moderately calcified patients (r = 0.43; p < 0.001). How-
ever, there was no correlation between FEP and serum
FGF23 (r = 0.11; p = 0.44) in severely calcified patients,
which supports that loss of FGF23 phosphaturic res-
ponse is associated with severe AAC (KI > 5). Further-
more, high serum PTH and low GFR adversely affect
VC and both are known contributors to high FEP in
CKD patients. However, Figure 1B and C (left panels)
Table 1 Characteristics of the overall sample and subgroups defined by KI values
Overall sample Subgroups defined by Kauppila Index
Characteristics (n = 178) KI = 0 (n = 57) KI 1–5 (n = 68) KI > 5 (n = 53) P value
Female 37.6 (67) 52.6 (30) 29.4 (20) 32.1 (17) 0.017
Age 69.1 ± 11.6 61 ± 14 71 ± 8 75 ± 6 0.001
BMI (Kg/m2) 28.5 ± 5.2 28.2 ± 6.1 29.2 ± 4.5 27.9 ± 4.9 0.342
Systolic BP (mmHg) 138.9 ± 21.2 134 ± 22 142 ± 19 140 ± 22 0.118
Diastolic BP (mmHg) 72.6 ± 10.9 74 ± 10 73 ± 11 70 ± 12 0.123
Pulse pressure (mmHg) 66.3 ± 19.9 60 ± 21 69 ± 19 70 ± 19 0.011
CKD Stage 0.169
CKD 3 33.7 (60) 42.1 (24) 35.3 (24) 22.6 (12)
CKD 4 66.3 (118) 57.9 (33) 64.7 (44) 77.4 (41)
Other conditions
Smokers 38.8 (69) 24.6 (14) 41.2 (28) 50.9 (27) 0.015
Diabetes mellitus 36.0 (64) 26.3 (15) 41.2 (28) 39.6 (21) 0.179
Hypertension 95.5 (170) 96.5 (55) 92.6 (63) 98.1 (52) 0.392
Etiology of CKD 0.011
Diabetic nephropathy 18.0 (32) 14 (8) 19.1 (13) 20.8 (11)
Nephrosclerosis 32.6 (58) 19.3 (11) 38.2 (26) 39.6 (21)
Chronic pyelonephritis 18.0 (32) 17.5 (10) 25 (17) 9.4 (5)
Unknown 15.2 (27) 22.8 (13) 10.3 (7) 13.2 (7)
Other 16.3 (29) 26.3 (15) 7.4 (5) 17 (9)
History of CD 38.8 (69) 17.5 (10) 42.6 (29) 56.6 (30) 0.001
Cardiac ischemia 11.2 (20) 5.3 (3) 13.2 (9) 15.1 (8) 0.212
CHF 23.0 (41) 7 (4) 26.5 (18) 35.8 (19) 0.001
Stroke 9.1 (16) 5.4 (3) 10.3 (7) 11.5 (6) 0.513
Peripheral vascular disease 16.9 (30) 12.3 (7) 17.6 (12) 20.8 (11) 0.482
ABI 0.92 ± 0.25 0.95 ± 0.2 0.91 ± 0.20 0.91 ± 0.33 0.552
ABI <0.9 37.6 (67) 28.1 (16) 42.6 (29) 41.5 (22) 0.193
Carotid ultrasound
IMT 0.83 ± 0.17 0.72 ± 0.14 0.86 ± 0.15 0.91 ± 0.18 0.001
Carotid plaque 73.6 (131) 45.6 (26) 82.4 (56) 92.5 (4950) 0.001
Atherosclerosis score 0.001
AS0/AS1 25.8 (46) 54.4 (31) 16.2 (11) 7.5 (4)
AS2 53.9 (96) 33.3 (19) 58.8 (40) 69.8 (37)
AS3 20.2 (36) 12.3 (7) 25 (17) 22.6 (12)
Laboratory data
Glucose (mg/dl) 112.7 ± 39.1 107 ± 32 118 ± 45 111 ± 37 0.283
Cholesterol (mg/dl 166.2 ± 30.9 171 ± 31 161 ± 32 168 ± 29 0.164
Albumin (g/dl) 4.3 ± 0.3 4.3 ± 0.4 4.3 ± 0.2 4.3 ± 0.2 0.629
CRP (mg/L) 5.2 ± 6.7 4.7 ± 5.3 4.8 ± 4.8 6.1 ± 9.7 0.468
Serum creatinine (mg/dl) 2.5 ± 0.7 2.5 ± 0.8 2.5 ± 0.7 2.6 ± 0.7 0.731
eGFR (ml/min) 27.2 ± 9.6 27.5 ± 9.9 28.2 ± 10.4 25.5 ± 7.9 0.309
Calcium (mg/dl) 9.2 ± 0.47 9.3 ± 0.46 9.2 ± 0.51 9.2 ± 0.41 0.311
Phosphate (mg/dl) 3.8 ± 0.6 3.9 ± 0.8 3.7 ± 0.5 3.8 ± 0.6 0.090
CaxP product (mg2/dl2) 34.8 ± 6.0 36.4 ± 7.3 33.6 ± 4.7 34.6 ± 5.5 0.036
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Table 1 Characteristics of the overall sample and subgroups defined by KI values (Continued)
Bone ALP (ug/L) 18.5 ± 9.7 17.4 ± 6.2 18.2 ± 9.0 20.1 ± 12.9 0.336
PTH(i) (pmol/L) 15.6 ± 9.9 16.2 ± 10.1 14.8 ± 9.9 15.9 ± 9.9 0.711
25(OH)vitamin D (ng/ml) 22.6 ± 13.6 23.5 ± 17.6 22.6 ± 12.7 21.5 ± 9.1 0.898
1.25(OH)2 vitamin D (pg/ml) 16.5 ± 10.4 15.7 ± 8.8 17.6 ± 12.7 15.9 ± 8.4 0.509
FEP (%) 35.8 ± 11.0 35.6 ± 11.4 36.2 ± 10.7 35.6 ± 11.2 0.931
FENa (%) 2.4 ± 1.1 2.4 ± 1.1 2.3 ± 0.9 2.6 ± 1.3 0.357
FECa (%) 0.95 ± 0.8 0.96 ± 0.9 0.99 ± 0.9 0.89 ± 0.5 0.790
FGF23 (RU/ml) 153.8 ± 111.5 136.1 ± 72.1 130.8 ± 81.9 202.4 ± 156.9 0.001
Soluble α-klotho (pg/ml) 482.2 ± 223.1 491 ± 250 466 ± 193 493 ± 230 0.739
Protein Intake (gr/Kg/day) 1.01 ± 0.27 1.01 ± 0.27 1.02 ± 0.28 1.02 ± 0.28 0.977
Medication
Calcium-containing P binders 12.9 (23) 19.3 (11) 8.8 (6) 11.3 (6) 0.202
Oral vitamin D3 39.3 (70) 36.8 (21) 45.6 (31) 34 (18) 0.386
Oral active vitamin D 4.5 (8) 5.3 (3) 5.9 (4) 1.9 (1) 0.659
Antiplatelet 48.3 (86) 31.6 (18) 50 (34) 64.2 (34) 0.002
Statins 70.8 (126) 59.6 (34) 76.5 (52) 75.5 (40) 0.080
Diuretics 64.6 (115) 56.1 (32) 60.3 (41) 79.2 (42) 0.025
Loop diuretics 77.3 (85) 67.7 (21) 79.5 (31) 82.5 (33) 0.311
Data are presented as % (n) = Percentage (number of patients) or Mean ± SD; P values were determined by Chi squared tests (or Fisher exact test in case of
expected frequencies lower than 5) for comparison of frequencies, and Kruskal Wallis tests for quantitative variables. Abbreviations: KI, Kauppila Index; BMI, Body
mass index; BP, Blood pressure; CD, Cardiovascular disease; CHF, Cardiac heart failure; ABI, Ankle, brachial index; IMT, Intima-media thickness; CRP, C reactive
protein; eGFR, Estimated GFR; Bone Alp, Bone alkaline phosphatase; FEP, FECa and FENa indicate fractional excretion of phosphate, calcium and sodium,
respectively; AS, Atherosclerosis score.
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either in the slopes for changes in FEP with increasing
PTH (KI = 0, r = 0.32, p < 0.014; KI = 1-5, r = 0.41, p <
0.001; KI = 5, r = 0.39, p = 0.003) or with decreasing eGFR
(KI = 0, r = −0.52, p < 0.001; KI = 1-5, r = −0.56, p < 0.001;
KI = 5, r = −0.39, p = 0.004) in all patients. The right panels
depict similar results also in patients with GFR under
30 ml/min. LR tests showed no interactions of KI tertiles
on the relationship of FEP with the variables PTH or
eGFR, and corroborated that only severe AAC (KI > 5)
had a significant interaction (LR test; p = 0.019) on the
association between FEP and FGF23 exclusively. Table 3Table 2 Multivariate linear regression analysis of factors asso
Model 1
Variable B 95% CI
Intercept −11.568 −17.218, 5.917
Male sex 1.237 0.058; 2.417
Age (y) 0.108 0.055; 0.162
CKD Stage 4 vs. 3 1.704 0.349; 3.058
Carotid plaque 1.978 0.560; 3.396
FEP −0.071 −0.127; -0.015
Ln(FGF23) 1.488 0.448; 2.529
Coefficient (B) and 95% confidence intervals (CI) for variables with a statistically sign
calcification (AAC), measured by Kauppila Index (KI), in a multivariate linear regressi
eGFR below 30 ml/min (Model 2). The coefficients of determination (r2) for Model 1shows the expected increases in AAC, FEP and FGF23 in
CKD stage 4 compared to stage 3.
Next, in an attempt to identify a threshold for the
degree of impairment in the phosphaturic response to
FGF23 that associated with severe AAC, linear and non
parametric plots examined the relationship between KI
scores and FEP/FGF23 ratios. A logarithmic (base 2)
transformation log2(FEP/FGF23) normalized the distri-
bution of FEP/FGF23 ratios. Figure 2 shows a biphasic
relationship between KI and the progressive reductions
in the phosphaturic response to FGF23, as FEP/FGF23
ratios decrease from 1/1 to 1/32. Average KI valuesciated with the severity of abdominal aortic calcification
Model 2
p B 95% CI p
<0.001 −10.887 −19.151; -2.622 0.010
0.040 1.490 −0.075; 3.055 0.062
<0.001 0.097 0.025; 0.168 0.009
0.014 N/A N/A N/A
0.007 2.491 0.429; 4.552 0.018
0.013 −0.083 −0.154; -0.012 0.023
0.005 1.839 0.438; 3.240 0.011
ificant (p < 0.05) contribution to explain the magnitude of abdominal aortic
on model including all the patients (Model 1) or patients with an estimated
and 2 were 0.301 and 0.286, respectively.
Figure 1 Resistance to FGF23-driven phosphaturia in CKD patients with severe abdominal aortic calcification. Linear regression models
for the relationship between FEP and serum FGF23 (A), or serum PTH (B) or estimated GFR (C) in the three subgroups of CKD patients defined
by their Kauppila Index (KI; Black: KI = 0, no calcification; Green: KI = 1 to 5, moderate calcification; Red: KI > 5, severe calcification) in the whole
patient population (Left side panels) or in patients with estimated GFR under 30 ml/min (Right side panels).
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above 1/3.9 despite reductions in FEP/FGF23 ratios from
1/1 to 1/3.9. Instead, KI scores markedly increased in
parallel with further reductions in FEP/FGF23 below the
threshold 1/3.9. More importantly, Table 4 shows the
results of logistic regression analyses conducted to identify
factors that independently associate with severe AAC
(KI > 5), which corroborated the significant independent
association of age, CKD stage, male gender, and the pres-
ence of CP with severe AAC (KI > 5), and also with the
log2(FEP/FGF23) < log2(1/3.9). Indeed, the odd ratios in
these highly sensitive logistic models (Table 4 and theTable 3 AAC and renal response to FGF23 in the course
of CKD
CKD3 (n = 60) CKD4 (n = 118) p value
AAC (KI) 2.8 ± 3.3 4.5 ± 4.6 0.02
FEP (%) 29.9 ± 8.1 38.8 ± 11.1 0.000001
FGF23 (RU/ml) 105.5 ± 87.8 178.4 ± 114.4 0.000001
Log2 (FEP/FGF23) −1.64 ± 0.84 - 2.04 ± 0.78 0.002
Klotho (pg/ml) 458.6 ± 236.5 494.2 ± 216.0 0.238ROC curve in Figure 3) suggested that the presence of
carotid plaques enhanced the chances of a patient to have
a KI > 5 by 5 to 9-fold (Compare Model 1 and 2 in
Table 3), and also, that in patients with FEP/FGF23 < 1/3.9
(serum FGF23 at least 3.9-fold higher than their respective
FEP), the chances to have KI > 5 increased by a factor of 3.
Accordingly, Figure 4 shows that patients with FEP/
FGF23 below 1/3.9, that is, with a worse phosphaturic
response to FGF23, showed a much higher average KI
than patients with a FEP/FGF23 ratio over 1/3.9.
Renal resistance to the phosphaturic actions of FGF23
develops with the progressive reductions in renal klotho in
the course of CKD [29]. However, serum klotho levels were
similar regardless of KI tertiles (Kruskal test; p = 0.86) or
CKD stage (Table 3) suggesting that serum soluble klotho
may not be an adequate marker of the magnitude of renal
klotho loss in CKD.
For further validation of the independent associ-
ation of a FEP/FGF23 ratio below 1/3.9 with severe
AAC we used a zero-inflated model, as 32% of our
patients showed a KI = 0. Table 5 shows that only
log2 (FEP/FGF23) < log2 (1/3.9) was associated directly
Figure 2 Biphasic relationship between the severity of abdominal aortic calcification with the phosphaturic response to FGF23. Linear
regression (Gray line) and non parametric regression (Black, continuous lines) depicting the relationships between the ratio of FEP/FGF23
(in logarithmic scale (base 2): log2(FEP/FGF23)), in the X axis, with the Kauppila Index (Y axis). The softer continuous lanes mark the dispersion
from the mean fit (see Methods for specifics). The box plot below the X axis shows that the cut-off point FEP/FGF23 = 1/3.9 coincides with the
median for the log2(FEP/FGF23) in our patient population. Note that the cut-off point FEP/FGF23 = 1/3.9 also marks an inflexion point for quite
distinct average changes for KI with changes in FEP/FGF23 ratios above and below the cut-off: No change in KI for FEP/FGF23 ratios above the
cut off; Parallel increases in KI with decreases in FEP/FGF23 ratios below the cut-off. Note in the X axis, the FEP/FGF23 ratios corresponding to the
values of log2(FEP/FGF23). The Box plot for KI distribution in our patients is depicted to the left of the Y axes.
Table 4 Logistic regression analysis of factors associated with severe abdominal aortic calcification
Model 1 Model 2
Variable Exp(B) 95% CI p Exp(B) 95% CI p
Intercept 0.003 0.000; 0.022 <.001 0.005 0.000; 0.050 <.001
Male sex 4.218 1.403; 14.207 0.014 4.167 1.050; 20.178 0.05
Age (y) - 50 1.111 1.047; 1.194 0.002 1.083 1.011; 1.177 0.037
CKD Stage 4 vs. 3 3.290 1.068; 10.773 0.041 N/A N/A N/A
Carotid plaque 6.131 1.605; 27.983 0.011 17.387 2.750;175.88 0.006
Cutoff point
((FEP/FGF23) < 1/3.9) 3.915 1.346; 12.364 0.015 6.873 1.703; 35.999 0.011
Exp (B) for the intercept measures the estimated odds of KI > 5 for the reference or zero values of the explanatory variables in the model. Exp (B) of the predictor
measures the odds ratio (B) associated to the variable category or 1 unit change depending of the nature of the variable. The table provides with Exp (B) and 95%
confidence intervals (CI) for variables with a statistically significant (p < 0.05) contribution to explain the magnitude of abdominal aortic calcification (AAC) in a
multivariate logistic regression model comparing KI > 5 vs. KI = 0 for all patients (Model 1), or among patients with an estimated GFR below 30 ml/min (Model 2).
The ratio FEP/FGF23 was introduced as a binary variable with a cutoff point of (FEP/FGF23) < (1/3.9) (or equivalently, log2(FEP/FGF23) < log2(1/3.9)). The ROC curve
in Figure 2 shows the high sensitivity and specificity of the logistic regression analysis in Model 1 (Area under the ROC curve = 0.89 and good model calibration,
as measured by Hosmer-Lemenshow goodness-of-fit test p = 0.95). For Model 2, the area under the ROC curve = 0.899 and HL test p = 0.55.
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Figure 3 Validation of the logistic model identifying factors independently associated with severe abdominal aortic calcification. ROC
curve depicting the high sensitivity of the logistic regression analysis of factors independently associated with severe abdominal aortic
calcification (KI < 5) vs. no calcification (KI = 0) including all patients. The ROC curve includes male gender, age, CKD stage, the presence of carotid
plaques, and the log2 (FEP/FGF23). The ratio FEP/FGF23 was introduced as a binary variable with a cutoff point of 1/3.9.
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http://www.biomedcentral.com/1471-2369/14/221and significantly with higher KI scores in both mo-
dels. Instead, age, CKD stage, male gender and ca-
rotid plaques, but not log2 (FEP/FGF23) < log2 (1/3.9)
associated negatively with KI = 0. These results sug-
gest that the progressive deterioration of the capacity
of the kidney to respond to FGF23 increasing FEP
may only associate with the severity of already on-
going AAC.
Discussion
The results of this cross-sectional study enhance our
current understanding on the key issue of the impact of
renal resistance to FGF23 on critical outcomes in CKD,
specifically, on the severity of AAC. To our knowledge,
this is the first study to present evidence of the asso-
ciation between renal resistance to the phosphaturic
actions of FGF23, but not to PTH-driven phosphaturia,
and the degree of AAC in patients CKD-stages 3 and 4.
Indeed, analysis of the relationship between KI scores
and FEP/FGF23 ratios in these patients identified a FEP/
FGF23 ratio, which marks a critical point for theimpairment in the renal response to FGF23 phosphaturic
actions that associates with a 3-fold enhancement of the
risk of severe AAC.
Our analysis of the relationship of abnormalities in the
phosphate/FGF23 axis with VC in CKD stages 3 and 4
supports a prior report [10] showing that high FGF23
but not high phosphate was independently associated
with VC, and contradicts the recent report by the CRIC
consortium in which neither serum FGF23 nor FEP were
significantly associated to calcification of either the cor-
onary artery or the thoracic aorta [14]. It is important to
highlight that in the CRIC study, measurements of
serum phosphate, FGF23 and FEP were obtained within
a year prior to obtaining coronary and aortic calcifica-
tion scores. In our study, a key role for an impaired
phosphaturic response to FGF23 in AAC was first sug-
gested by the finding that increases in FEP associated
negatively with AAC in multivariate analysis, independ-
ently of the CKD stage.
To evaluate VC, we measured abdominal aortic calcifi-
cation (AAC) with the semiquantitative but cost/effective
Figure 4 The severity of AAC is higher in patients with a FEP/FGF23 below the threshold FEP/FGF23 = 1/3.9. Box-plot analysis of the AAC
measured by the Kauppila index (KI) in patients with a ratio FEP/FGF23 below 1/3.9 or equal or above 1/3.9. Patients were divided in two groups
defined by the median of the ratio (1/3.9).
Table 5 Zero-inflated regression analysis of factors associated with abdominal aortic calcification, taking Negative
binomial distribution to model KI scores
Model 1 Model 2
Variable Exp(B) 95% CI p Exp(B) 95% CI p
KI score KI score
Intercept 1.568 0.897: 2.740 0.114 2.023 1.090; 3.756 0.026
Male sex 1.086 0.837; 1.410 0.534 1.115 0.830; 1.498 0.471
Age (y) - 50 1.022 1.004; 1.040 0.015 1.010 0.989; 1.032 0.349
CKD Stage 4 vs. 3 1.232 0.941; 1.612 0.128 N/A N/A N/A
Carotid plaque 1.266 0.844; 1.897 0.254 1.577 0.943; 2.636 0.082
Cutoff point
((FEP/FGF23) < 1/3.9) 1.817 1.422; 2.320 <0.001 1.847 1.374; 2.482 <0.001
Inflation in KI = 0 Inflation in KI = 0
Intercept 17.629 4.113; 75.551 <0.001 6.329 1.506; 26.596 0.012
Male sex 0.250 0.092; 0.682 0.007 0.305 0.078; 1.189 0.087
Age (y) - 50 0.919 0.875; 0.965 0.001 0.905 0.846; 0.969 0.004
CKD Stage 4 vs. 3 0.347 0.128; 0.942 0.038 N/A N/A N/A
Carotid plaque 0.271 0.100; 0.738 0.011 0.337 0.080; 1.410 0.136
Cutoff point
((FEP/FGF23) < 1/3.9) 1.047 0.410; 2.677 0.923 0.958 0.273; 3.356 0.946
Exp (B) for the first and second intercepts are the estimated KI score and the estimated odds of KI = 0 respectively for a patient with the reference categories or
zero values of the explanatory variables in the model. Additionally Exp (B) of the predictor measures the odds ratio (B) associated to the variable category or 1
unit change depending of the nature of the variable. The table provides with Exp (B) and 95% confidence intervals (CI) for variables with a statistically significant
(p < 0.05) contribution to explain the score of abdominal aortic calcification (AAC) measured by KI and the high frequency of no ACC (KI = 0) simultaneously in a
multivariate Zero-inflated regression model in all patients (Model 1), or among patients with an estimated GFR below 30 ml/min (Model 2). The ratio FEP/FGF23
was introduced as a binary variable with a cutoff point of (FEP/FGF23) < (1/3.9).
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calcium scores from computer beam tomography [30] and
reflects arterial stiffness better than coronary calcium
scores [31-33]. Also, a KI > 5 can be considered as severe
AAC because it was shown to increase by a factor of 3.7
the risk of adverse cardiovascular events in a large cohort
of prevalent dialysis patients [34].
The accuracy of FEP measurements can also be
questioned, as urinary phosphate excretion depends
upon several factors, including not only the integrity of
glomerular and tubular renal function, but also dietary
phosphate intake (mainly in proteins), serum levels of
the phosphaturic hormones FGF23 and PTH, and renal
content of Klotho, the co-receptor required for FGF23
actions [35]. However, there were no differences in esti-
mated GFR, serum PTH, or in protein intake, an estima-
tion of P intake [36] when patients were categorized by
their KI. Furthermore, FEP not only increases in re-
sponse to FGF23, but also to PTH, or to decreases in
eGFR. However, the slopes of the linear regression ana-
lysis of FEP with PTH or eGFR were similar among KI
groups in the whole population, and also in patients with
eGFR below 30 ml/min. This demonstrated an intact
renal response to PTH phosphaturic actions and the
expected increases in FEP with the worsening of renal
function. Instead, FEP and FGF23 increased in parallel
only in the non-calcified and moderately calcified
patients. No increases in FEP occurred with major
increases in serum FGF23 in severely calcified patients,
supporting the negative association between FEP with
AAC identified in the multivariate analysis. LR tests con-
firmed the results of the linear regression analysis. Only
the slopes for FEP with increases in FGF23 were affected
by the highest KI levels. Neither the slopes of the associ-
ations between FEP with PTH nor those of FEP with
eGFR showed significant interactions with KI values. Al-
though the phosphaturic response to PTH and FGF23
involves identical sodium-phosphate co-transporters in
renal proximal tubular cells, the mechanisms of actions
of these potent phosphaturic hormones are quite differ-
ent. While PTH, through its receptor 1 and a cAMP me-
diated mechanism, modulates the endocytosis of the
NaPi IIa cotransporters to prevent P reabsorption [37],
FGF23 requires the co-receptor klotho to activate the
FGFR to reduce renal content of NaPiII channels [29].
The progressive decreases in klotho in the course of
CKD partly account for the renal resistance to FGF23.
Thus, our findings demonstrating that FEP increases
in parallel with the increases in serum PTH regardless
of KI but not with the increases in FGF23 underscore
our hypothesis of a role for renal resistance to FGF23
in the severity of AAC. Our results of unchanged
soluble serum klotho with progressive increases in
the resistance to FGF23 phosphaturic actions supportprevious reports suggesting that soluble serum klotho
is not an accurate marker of renal klotho loss. It is
likely that urinary klotho represents a better indicator
of renal klotho loss, as demonstrated by Akimoto
et al. [38] and supported by the new understanding of
renal klotho cleavage and actions [29].
The multivariate analysis also has limitations: Its
determination coefficients indicate that these models
explain only 28% of the variability in KI. Also, KI
values were 0 in a third of patients. However, highly
sensitive logistic regression analysis confirmed the key
role of impaired phosphaturic response to FGF23 in
AAC, as in patients with FEP/FGF23 ratios below 1/3.9
the chances to develop severe AAC increased by 3 to 4-
fold. Importantly, zero- inflated and binomial models have
corroborated the accuracy of our logistic model in iden-
tifying variables associated with severe AAC in CKD
patients, including the new threshold of FEP/FGF23 ratios
below 1/3.9, which strongly associated to a higher risk for
severe AAC. Indeed, KI scores did not change with
progressive reductions in the renal response to FGF23
phosphaturic actions before reaching an almost 4-fold
elevation in FGF23 without changes in FEP, but markedly
increased in parallel with further reductions in the phos-
phaturic response to FGF23 as measured by FEP/FGF23
ratios below 1/3.9.
Our results are in agreement with a very recent report by
Dominguez et al., demonstrating that the association bet-
ween FGF23 levels and adverse cardiovascular outcomes
was modified by FEP values. In models adjusted for CVD
risk factors, kidney function, and PTH, those patients who
had FGF23 above the median but FEP below the median
had the highest risks of both all-cause mortality and CVD
events [19]. In summary, the results of this cross-sectional
study suggest that the evaluation of FGF23 levels in CKD
patients should be accompanied by the assessment of the
capacity of the damaged kidney to induce an adequate
phosphaturic response. However, prospective studies are
necessary to validate this cut-off of FEP/FGF23 = 1/3.9 as a
predictive marker of the degree of renal resistance to
FGF23 phosphaturic actions which, if surpassed, will mark-
edly enhance the chances of severe AAC.
Also, as proven for hemodialysis patients [23], athero-
matosis is a risk factor for AAC in non dialyzed CKD
patients. The logistic analyses showed that in patients
with carotid plaques the chances of severe AAC increa-
sed by 5 to 9-fold, while the zero-inflated model cor-
roborated the negative association between age, male
gender, CKD stage, and also of carotid plaques with the
number of patients with KI = 0. Undoubtedly, proper
patient management to attenuate the onset and/or pro-
gression of VC in early CKD should rightly focus on the
prevention/treatment of co-morbid conditions predispo-
sing to atheromatosis.
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A FEP/FGF23 > 1/3.9 may help protect CKD patients
from severe AAC independently of age, gender, CKD
stage and the presence of clinical atheromatosis in the
carotid arteries. Undoubtedly, these findings need to be
validated in prospective, well powered clinical trials.
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